Cancer Care in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for adults and adolescents (12+) with newly diagnosed advanced classical Hodgkin lymphoma—positioning it as the first immunotherapy-based regimen for this setting in the EU. CLL Treatment Update: AbbVie’s VENCLYXTO (venetoclax) got an expanded EU label for first-line chronic lymphocytic leukemia, adding fixed-duration combinations with acalabrutinib (± obinutuzumab) and with ibrutinib across EU states including Liechtenstein. Bladder Cancer Option for Cisplatin-Ineligible Patients: The EU CHMP issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin followed by adjuvant treatment after radical cystectomy for resectable muscle-invasive bladder cancer in adults who can’t have cisplatin chemotherapy. Transplant Breakthrough: Hansa Biopharma reported strong one-year outcomes for Idefrix (imlifidase) in highly sensitised kidney transplant patients, with 90% graft failure-free survival at one year. Heat & Health Risk: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, underscoring the need for cooling and hydration. Disability Benefit Holiday Rules: The UK DWP confirmed strict Personal Independence Payment holiday rules for trips over four weeks, with potential fines or payment stops if claimants don’t report changes.